文献速递妇科生殖医学

二甲双胍与罗格列酮单用及联用治疗肥胖PCOS的随机对照试验

Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.
PubMed 文献 · Fertil Steril · 2019-11-09

该前瞻性随机对照试验纳入肥胖且胰岛素抵抗的PCOS女性,比较二甲双胍1500 mg/d、罗格列酮4 mg/d及二甲双胍1000 mg/d联合罗格列酮4 mg/d治疗6个月的效果。三组代谢指标均较基线改善,二甲双胍1500 mg/d组体重下降更明显,罗格列酮单用或联用组总胆固醇和甘油三酯下降更显著。

要点

  • 二甲双胍1500 mg/d组体重下降幅度大于其他两组。
  • 罗格列酮单用或联合二甲双胍组总胆固醇和甘油三酯下降更明显。
  • 三组痤疮评分、体重、BMI、腰围、腰臀比及血清睾酮均显著下降。

核心结论

  • 考虑二甲双胍对减重的益处,对肥胖且胰岛素抵抗的PCOS女性推荐高剂量二甲双胍1500 mg/d联合生活方式调整。
  • 对血脂异常的女性可考虑罗格列酮单用或联合低剂量二甲双胍加生活方式调整。

研究设计与样本

  • 前瞻性随机对照试验,在三级教学医院开展。
  • 纳入肥胖(BMI≥25 kg/m2)且胰岛素抵抗、符合Rotterdam诊断标准的中国PCOS女性。
  • 组1:68例接受二甲双胍1500 mg/d;组2:67例接受罗格列酮4 mg/d;组3:69例接受二甲双胍1000 mg/d联合罗格列酮4 mg/d,疗程6个月,均接受相同饮食和规律运动生活方式建议。
  • 采用意向性分析(intention-to-treat)。

主要发现

  • 基线参数在三组间无统计学显著差异。
  • 治疗6个月后,大多数参与者月经模式改善。
  • 痤疮评分、体重、BMI、腰围、腰臀比及血清睾酮均出现统计学显著下降。
  • 各组胰岛素、碳水化合物和脂质代谢指标较基线明显改善。
  • 三组间比较,二甲双胍1500 mg/d组体重下降更明显;罗格列酮单用或联合二甲双胍组总胆固醇和甘油三酯下降更显著。

关键数值与推荐

  • 二甲双胍剂量:组1为1500 mg/d,组3为1000 mg/d。
  • 罗格列酮剂量:组2和组3均为4 mg/d。
  • 纳入标准:BMI≥25 kg/m2、胰岛素抵抗、符合Rotterdam标准。
  • 疗程:6个月。
  • 临床试验注册号:ChiCTR-TRC-13003642。

临床怎么用

  • 对肥胖且胰岛素抵抗的PCOS女性,可考虑高剂量二甲双胍1500 mg/d联合生活方式调整。
  • 对血脂异常的女性,可考虑罗格列酮单用或联合低剂量二甲双胍加生活方式调整。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effects of metformin, rosiglitazone, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance. DESIGN: Prospective randomized controlled trail. SETTING: Tertiary teaching hospital. PATIENT(S): Obese Chinese women (body mass index [BMI] ≥25 kg/m2) with insulin resistance who fulfilled the Rotterdam criteria of PCOS. INTERVENTION(S): In group 1, 68 patients administered metformin (1,500 mg/day); in group 2, 67 patients administered rosiglitazone (4 mg/day); in group 3, 69 patients administered metformin (1,000 mg/day) and rosiglitazone (4 mg/day) for 6 months, all with the same diet and regular exercise lifestyle recommendation. MAIN OUTCOME MEASURE(S): Average menstrual interval, anthropometric measurements, androgen-related parameters, and metabolic features of insulin, carbohydrates, and lipids, with intention-to-treat analysis. RESULT(S): The baseline parameters showed no statistically significant differences. After the 6-month treatment, most participants showed an improved menstrual pattern. There were statistically significant decreases in acne scores, weight, BMI, waist circumference, waist-to-hip ratio, and serum testosterone. The metabolic indexes of insulin, carbohydrates, and lipids were improved obviously compared with the baseline in each group. Among the three groups, the patients administered 1,500 mg/day metformin experienced greater reductions in weight. However, the rosiglitazone users (alone or combined with metformin) showed a more notable decline in total cholesterol and triglyceride levels. CONCLUSION(S): Considering the benefits of metformin on weight loss, high-dose metformin (1,500 mg/day) along with lifestyle modification should be recommended for obese, insulin-resistant women with PCOS. Rosiglitazone alone or combined with low-dosage metformin plus lifestyle modification should be considered for the women with abnormal lipid profiles. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-TRC-13003642 (Chinese Clinical Trial Registry).

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Li Y, Tan J, Wang Q, et al. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2019. PMID: 31718828. doi:10.1016/j.fertnstert.2019.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。